Over the past years, most of Hadasit Bio's portfolio companies have received recognition from global pharmaceutical companies, like TEVA, Sanofi and other leading players in the field. They have joined Hadasit Bio-Holdings as partners by making direct investments in portfolio companies after recognizing the strong scientific base and the developmental abilities of Hadasit's holding companies. This support from industry leaders validates our efforts and serves to further advance these portfolio companies into the growing medical markets.
At a time when industry trends and market conditions often overshadow the progress of any single company, we see it as an obligation to our shareholders to provide an investor update and outline our progress, current expectations and growth milestones that we are working to achieve.
Business Overview & Background:
Hadasit Bio-Holdings Ltd. was established by an arm of Hadassah Hospitals which runs the business operations of two hospitals in Jerusalem. The company was formed with the goal of advancing the knowledge and experience accumulated in the hospital's research labs, and was listed on the Tel Aviv Stock Exchange to enable public investment into this research.
The close ties between Hadassah Hospital and Hadasit Bio provide many unique advantages that most companies can only dream of including: direct access to a stream of ideas, research, cooperative abilities, from the best minds and researchers in their fields, access to facilities that perform clinical trials and hospital wards that provide maximum efficiency and great savings. In addition, the companies enjoy the Hadassah Medical Organization's centers of excellence - a leader in innovation and infrastructure among the hospitals in Israel and the world.
As a result, Hadasit currently has seven portfolio biotechnology companies, all of which have passed the feasibility proving sta
|SOURCE Hadasit Bio-Holdings Ltd.|
Copyright©2010 PR Newswire.
All rights reserved